From the CMS doc “Medicare Drug Value Negotiation Program: Chosen Medicine for Preliminary Value
Applicability Yr 2027“:
On January 17, 2025, CMS introduced the collection of the beneath record of 15 medication lined below Medicare Half D for the second cycle of negotiations (preliminary value applicability yr 2027), primarily based on whole gross lined prescription drug prices below Medicare Half D and different standards as required by the regulation.
With the Trump inauguration to happen on Monday, will the Medicare Drug Value Negotiation course of change with the brand new administration? Anna Kaltenboeck notes in EndPoints Information:
…the subsequent administration is not going to have “blanket authority to alter the core components of the regulation,” sure features of the method could be modified with out legislative motion.
For instance, CMS may alter its steerage or the way it interprets components of the regulation, reminiscent of what number of occasions it meets with drugmakers, or what number of listening periods it holds. “The diploma to which they play hardball with producers within the course of may change,” she mentioned.
